MESOBLAST Business Summary

Mesoblast Ltd (MESO) is a commercial-stage biopharmaceutical leader specializing in allogeneic, "off-the-shelf" cellular medicines derived from its proprietary mesenchymal lineage cell technology platform. The company generates revenue primarily through direct product sales of Ryoncil (remestemcel-L), the first FDA-approved mesenchymal stromal cell (MSC) therapy for pediatric steroid-refractory acute graft-versus-host disease (SR-aGvHD), as well as through milestone payments and royalties from global licensing partnerships in Japan and Europe. Mesoblast operates as a single segment focused on the development and commercialization of its MSC platform, with a late-stage pipeline targeting high-unmet-need conditions including chronic heart failure (Revascor) and chronic low back pain. Positioned as a pioneer in regenerative medicine, Mesoblast maintains a dominant market share in pediatric SR-aGvHD and is aggressively expanding into the adult market, competing directly with firms such as Cynata Therapeutics, Praxis Precision Medicines, Krystal Biotech, and Cytokinetics. The company was founded by Dr. Silviu Itescu, who continues to serve as Chief Executive Officer and is a renowned physician-scientist with extensive expertise in immunology and regenerative medicine. The executive leadership team includes Chief Financial Officer James O'Brien, appointed in late 2025 to steer the firm's commercial transition, and Chief Technology and R&D Officer Dr. Eric Rose, a pioneer in heart transplantation and former Chairman of Surgery at Columbia University. Governance is overseen by Non-Executive Chair Philip Facchina, who assumed the role in January 2026, alongside Vice-Chair William Burns and Audit Chair Lyn Cobley. Mesoblast is supported by a robust institutional investor base, including the Thorney Investment Group and Josaka Investments, and maintains a strategic board composition designed to maximize U.S. commercial delivery and long-term shareholder value.